1. The efficacy and safety of adding anlotinib in gradual progression on third-generation EGFR-TKIs for EGFR-mutant advanced nonsmall cell lung cancer
   Hai Xiang et al, 2024, Anti-Cancer Drugs CrossRef
2. The efficacy of almonertinib and anlotinib combination therapy for advanced non‐small‐cell lung cancer patients who continued to experience cancer progression during third‐generation EGFR‐TKI treatment: a retrospective study
   Yu Zhang et al, 2024, Thoracic Cancer CrossRef